

**EUROPEAN
CURRICULUM VITAE
FORMAT**



PERSONAL INFORMATION

Name	RIZZATO MARIO DOMENICO
Profession	Medical Oncologist
E-mail	mariodomenico.rizzato@iov.veneto.it
Nationality	Italian
Date of birth	09 th AUGUST 1986
Work Address	U.O.C. Oncologia 1 Istituto Oncologico Veneto - IRCCS Via Gattamelata, 64 - 35128 Padua, ITALY

WORK EXPERIENCE

- | | |
|---|---|
| <ul style="list-style-type: none">• Dates (from – to)• Name and address of employer<ul style="list-style-type: none">• Type of business or sector• Occupation or position held• Main activities and responsibilities | October 2020 - Present
Università degli Studi di Padova, Istituto Oncologico Veneto - IRCCS, Padua, Italy
Medical Oncology
PhD fellow in Oncology
Project of Research: Advanced Biliary Tract Cancers, molecular characterization for prognostic and predictive analyses. |
| <ul style="list-style-type: none">• Dates (from – to)• Name and address of employer<ul style="list-style-type: none">• Type of business or sector• Occupation or position held• Main activities and responsibilities | February – November 2014
U.O.C. Oncologia Medica 1, Istituto Oncologico Veneto – IRCCS
Medical Oncology
Fellow Physician
Fellow Physician in clinical practice and clinical research. |

EDUCATION AND TRAINING

- | | |
|--|---|
| <ul style="list-style-type: none">• Dates (from – to)• Name and type of organisation providing education and training• Principal subjects/occupational skills covered• Title of qualification awarded• Level in national classification (if appropriate) | November 2015 - October 2020
Università degli Studi di Padova, Istituto Oncologico Veneto - IRCCS, Padua, Italy
Director Prof. PF Conte. Fellowship Training Program in Medical Oncology
Inpatient and ambulatory care of oncologic patients. Conduction of phase II-III and IV clinical trials in medical oncology field as sub-investigator. Member of multidisciplinary team for patients treatment.
Specialization degree in Medical Oncology
110/110 cum laude. Thesis: “Emerging new targets in biliary tract cancers: descriptive and prognostic analyses from a detailed pathological and molecular characterization of a large real-world clinical dataset” |
|--|---|

- Dates (from – to) December 2014 – August 2015
- Name and type of organisation providing education and training Università degli Studi di Padova, Istituto Oncologico Veneto – IRCCS, Padua, Italy Fellowship Training Program in Radiotherapy
- Principal subjects/occupational skills covered Inpatient and ambulatory care of oncologic patients. Member of multidisciplinary team for patients treatment.
- Title of qualification awarded

- Dates (from – to) October 2013
- Name and type of organisation providing education and training University of Padua, Padua, Italy - Medicine and Surgery School
- Title of qualification awarded Medical Doctor
- Level in national classification 110/110. Thesis: “Adjuvant chemotherapy for soft tissue sarcomas: analysis of record of cases of Istituto Oncologico Veneto”

**PERSONAL SKILLS
AND COMPETENCES**

Acquired in the course of life and career but not necessarily covered by formal certificates and diplomas.

MOTHER TONGUE

ITALIAN

OTHER LANGUAGES

ENGLISH

- Reading skills
- Writing skills
- Verbal skills

good
good
good

**ORGANISATIONAL SKILLS
AND COMPETENCES**

Coordination and administration of people, projects and budgets; at work, in voluntary work (for example culture and sports) and at home, etc.

Management of cancer patients within multidisciplinary teams
Writing of research projects
Conduction of clinical trials (Phase II, III and IV) as co-investigator according to GCP training (performed on September 2020)

**TECHNICAL SKILLS
AND COMPETENCES**

With computers, specific kinds of equipment, machinery, etc.

Office package
Researches in public database

ANNEXES

Co-author of peer-reviewed scientific papers and meeting abstracts in medical oncology field

SCIENTIFIC ACTIVITIES

Scientific Publications:

1. Brunello A, **Rizzato MD**, Rastrelli M, Roma A, Maruzzo M, Basso U, Fiduccia P, Buzzaccarini MS, Scarzello G, Rossi CR, Zagonel V. Adjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience. **J Cancer Res Clin Oncol**. 2016 Mar;142(3):679-85. doi: 10.1007/s00432-015-2065-4.
2. Schirripa M, Pasqualetti G, Giampieri R, Scartozzi M, Lonardi S, Rumanò L, Bergamo F, Stragliotto S, Murgioni S, Alberti G, **Rizzato MD**, Prete AA, Puzzone M, Pusceddu V, Ziranu P, Pani F, Mariotti S, Zagonel V, Monzani F, Loupakis F. Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study. **Clin Colorectal Cancer**. 2018 Sep;17(3):e601-e615. doi: 10.1016/j.clcc.2018.05.013.
3. Pelizzaro F, Sammarco A, Dadduzio V, Pastorelli D, Giovanis P, Soldà C, **Rizzato MD**, Lombardi G, Lonardi S, Peserico G, Imondi A, Sartori A, Maddalo G, Farinati F. Capecitabine in advanced hepatocellular carcinoma: A multicenter experience. **Dig Liver Dis**. 2019 Dec;51(12):1713-1719.
4. Casadei-Gardini A, Solaini L, Riggi L, Molinaro E, Dadduzio V, **Rizzato MD**, Pellino A, Faloppi L, Marisi G, Ulivi P, Canale M, Orsi G, Rovesti G, Andrikou K, Spallanzani A, Gelsomino F, Foschi FG, Conti F, Cucchetti A, Ercolani G, Biason P, Lonardi S, Cascinu S, Scartozzi M. Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort. **Gastrointest Tumors**. 2019 Oct;6(3-4):71-80.
5. Casadei-Gardini A, Cabibbo G, Dadduzio V, Orsi G, Vukotic R, **Rizzato MD**, Rossi M, Guarneri V, Lonardi S, D'Agostino D, Celsa C, Rovesti G, Rimini M, Andreone P, Zagonel V, Scartozzi M, Johnson P, Cascinu S, Cucchetti A. Validation and refinement of PROSASH model using the neutrophil-to-lymphocyte ratio in patients with HCC receiving sorafenib. **Liver Cancer International**, (2020) 1(1), 6-11. doi: 10.1002/lci2.12
6. Casadei-Gardini A, Marisi G, Dadduzio V, Gramantieri L, Faloppi L, Ulivi P, Foschi FG, Tamburini E, Vivaldi C, **Rizzato MD**, Ielasi L, Canale M, Conti F, Rudnas B, Fornaro L, Silvestris N, Silletta M, Cardellino GG, Lonardi S, Fornari F, Orsi G, Rovesti G, Zagonel V, Cascinu S, Scartozzi M. Association of NOS3 and ANGPT2 gene polymorphisms with survival in patients with hepatocellular carcinoma receiving sorafenib: results of the multicenter prospective INNOVATE study. **Clin Cancer Res**. May 5, 2020 doi: 10.1158/1078-0432.CCR-19-3897
7. Caputo F, Dadduzio V, Tovoli F, Bertolini G, Cabibbo G, Cerma K, Vivaldi C, Faloppi L, **Rizzato MD**, Piscaglia F, Celsa C, Fornaro L, Marisi G, Conti F, Silvestris N, Silletta M, Lonardi S, Granito A, Stornello C, Massa V, Astaro G, Delcuratolo S, Cascinu S, Scartozzi M, Casadei-Gardini A. The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. **PLoS One**. 2020 May 7;15(5):e0232449. doi: 10.1371/journal.pone.0232449. PMID: 32379785; PMCID: PMC7205300.

- Casadei-Gardini A, Dadduzio V, Rovesti G, Cabibbo G, Vukotic R, **Rizzato MD**, Orsi G, Rossi M, Guarneri V, Lonardi S, D'agostino D, Celsa C, Andreone P, Zagonel V, Scartozzi M, Cascinu S, Cucchetti A. Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib. *Medicine* (Baltimore). 2020 May 29;99(22):e19958. doi: 10.1097/MD.00000000000019958. PMID: 32481366.

Meeting Abstracts:

- Vivaldi C, Buccianti P, Musettini G, Bergamo F, **Rizzato MD**, Sainato A, Martignetti A, Lucchesi S, Franceschi M, Boso C, Pasqualetti F, Ginocchi L, Di Clemente F, Gonnelli A, Urbani L, Montrone S, Maretto I, Sidoti F, Falcone A, Masi G. TRUST: Phase II trial of induction chemotherapy (CT) with FOLFOXIRI + bevacizumab (BV) followed by chemo-radiotherapy (CRT) + BV and surgery in locally advanced rectal carcinoma (LARC). *Annals of Oncology* (2016) 27 (6): 149-206. 10.1093/annonc/mdw370
- Dadduzio V, **Rizzato MD**, Ramondo G, Vivaldi C, Milella M, Brandi G, Cereda S, Murgioni S, Cardellino GG, Filippi R, Santini D, Pasquini G, Intini R, Vaccaro V, Palloni A, Reni M, Musettini G, Gringeri E, Aliberti C, Zagonel V. Advanced intrahepatic cholangiocarcinoma (iCCA) treated with arterial-directed therapies (ADT): outcomes and safety from a multicenter Italian experience. *Annals of Oncology* (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282
- Casadei-Gardini A, Marisi G, Dadduzio V, Faloppi L, Ielasi L, Vivaldi C, **Rizzato MD**, Fornaro L, Lonardi S, Gramantieri L, Pecora I, Silvestris N, Fornari F, Orsi G, Rovesti G, Santini D, Zagonel V, Cascinu S, Scartozzi M. Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in HCC patients treated with sorafenib: Final results of INNOVATE study. *Annals of Oncology* (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247
- Procaccio L, Del Re M, Crucitta S, Gianfilippo G, Daniel F, Di Antonio V, Gallimberti S, Munari G, Zanella G, Alberti G, **Rizzato MD**, Rasola C, Maddalena G, Prete AA, Bergamo F, Zagonel V, Lonardi S, Danesi R, Fassan M, Loupakis F. A real-world application of liquid biopsy (LB) in metastatic colorectal cancer (mCRC). *Journal of Clinical Oncology* 2020 38:4_suppl, 48-48

SCIENTIFIC AFFILIATIONS

Italian Association of Medical Oncology - AIOM

I give permission to data treatment in accordance to 196/03 Italian laws.

Padua, 28 Nov 2020

